BACKGROUND: The effect of increasing negative margin width after breast-conserving therapy (BCT) on local recurrence (LR) is controversial. LR rates vary by subtype, with the highest rates seen in triple-negative breast cancer (TNBC). This study examined LR rates in relationship to margin width in TNBC treated with BCT. METHODS: Women with TNBC who underwent BCT between 1999 and 2009 were identified. Margins were defined as positive (ink on tumor), 0.1-2.0, and 2 mm. Patients with positive margins were excluded. Statistical comparisons were by t test, Fisher's exact test, and Wilcoxon rank sum test. Cumulative incidence of LR was compared by competing-risks methodology. RESULTS: Of 535 cancers, 71 had margins ≤2 mm and 464 had margins >2 mm. At a median follow-up of 84 months (range 8-165 months), there were 37 local, 18 regional, and 77 distant recurrences or deaths as first events. Ten patients had a locoregional recurrence before planned radiotherapy and were excluded from cumulative incidence analyses. The cumulative incidence of LR at 60 months for margins ≤2 mm was 4.7 % (95 % confidence interval 0-10.0) and for >2 mm was 3.7 % (1.8, 5.5) (p = 0.11). After controlling for chemotherapy and tumor size, there was no difference in LR between the two margin groups (p = 0.06). A difference in the risk of distant recurrence or death was not observed (p = 0.53). CONCLUSIONS: Margin width of >2 mm was not associated with reduced LR rates. These data support a negative margin definition of no ink on tumor, even in this high-risk TNBC cohort.
BACKGROUND: The effect of increasing negative margin width after breast-conserving therapy (BCT) on local recurrence (LR) is controversial. LR rates vary by subtype, with the highest rates seen in triple-negative breast cancer (TNBC). This study examined LR rates in relationship to margin width in TNBC treated with BCT. METHODS:Women with TNBC who underwent BCT between 1999 and 2009 were identified. Margins were defined as positive (ink on tumor), 0.1-2.0, and 2 mm. Patients with positive margins were excluded. Statistical comparisons were by t test, Fisher's exact test, and Wilcoxon rank sum test. Cumulative incidence of LR was compared by competing-risks methodology. RESULTS: Of 535 cancers, 71 had margins ≤2 mm and 464 had margins >2 mm. At a median follow-up of 84 months (range 8-165 months), there were 37 local, 18 regional, and 77 distant recurrences or deaths as first events. Ten patients had a locoregional recurrence before planned radiotherapy and were excluded from cumulative incidence analyses. The cumulative incidence of LR at 60 months for margins ≤2 mm was 4.7 % (95 % confidence interval 0-10.0) and for >2 mm was 3.7 % (1.8, 5.5) (p = 0.11). After controlling for chemotherapy and tumor size, there was no difference in LR between the two margin groups (p = 0.06). A difference in the risk of distant recurrence or death was not observed (p = 0.53). CONCLUSIONS: Margin width of >2 mm was not associated with reduced LR rates. These data support a negative margin definition of no ink on tumor, even in this high-risk TNBC cohort.
Authors: Farrell C Adkins; Ana Maria Gonzalez-Angulo; Xiudong Lei; Leonel F Hernandez-Aya; Elizabeth A Mittendorf; Jennifer K Litton; Jamie Wagner; Kelly K Hunt; Wendy A Woodward; Funda Meric-Bernstam Journal: Ann Surg Oncol Date: 2011-09-27 Impact factor: 5.344
Authors: Andrea L Russo; Nils D Arvold; Andrzej Niemierko; Nathan Wong; Julia S Wong; Jennifer R Bellon; Rinaa S Punglia; Mehra Golshan; Susan L Troyan; Jane E Brock; Jay R Harris Journal: Breast Cancer Res Treat Date: 2013-07-09 Impact factor: 4.872
Authors: Jona A Hattangadi-Gluth; Jennifer Y Wo; Paul L Nguyen; Rita F Abi Raad; Meera Sreedhara; Andrzej Niemierko; Phoebe E Freer; Dianne Georgian-Smith; Jennifer R Bellon; Julia S Wong; Barbara L Smith; Jay R Harris; Alphonse G Taghian Journal: Int J Radiat Oncol Biol Phys Date: 2011-05-19 Impact factor: 7.038
Authors: Laurence E McCahill; Richard M Single; Erin J Aiello Bowles; Heather S Feigelson; Ted A James; Tom Barney; Jessica M Engel; Adedayo A Onitilo Journal: JAMA Date: 2012-02-01 Impact factor: 56.272
Authors: Zachary S Zumsteg; Monica Morrow; Brittany Arnold; Junting Zheng; Zhigang Zhang; Mark Robson; Tiffany Traina; Beryl McCormick; Simon Powell; Alice Y Ho Journal: Ann Surg Oncol Date: 2013-05-19 Impact factor: 5.344
Authors: Laura S Dominici; Monica Morrow; Elizabeth Mittendorf; Jennifer Bellon; Tari A King Journal: Curr Probl Surg Date: 2016-11-29 Impact factor: 1.909
Authors: Laura H Rosenberger; Anita Mamtani; Sarah Fuzesi; Michelle Stempel; Anne Eaton; Monica Morrow; Mary L Gemignani Journal: Ann Surg Oncol Date: 2016-07-12 Impact factor: 5.344
Authors: Julia C Radosa; Anne Eaton; Michelle Stempel; Amrin Khander; Cornelia Liedtke; Erich-Franz Solomayer; Maria Karsten; Melissa Pilewskie; Monica Morrow; Tari A King Journal: Ann Surg Oncol Date: 2016-10-25 Impact factor: 5.344
Authors: A Kümmel; S Kümmel; J Barinoff; F Heitz; J Holtschmidt; W Weikel; F Lorenz-Salehi; A du Bois; P Harter; A Traut; J U Blohmer; B Ataseven Journal: Geburtshilfe Frauenheilkd Date: 2015-07 Impact factor: 2.915
Authors: Rachel A Freedman; Christina A Minami; Eric P Winer; Monica Morrow; Alexander K Smith; Louise C Walter; Mina S Sedrak; Haley Gagnon; Adriana Perilla-Glen; Hans Wildiers; Tanya M Wildes; Stuart M Lichtman; Kah Poh Loh; Etienne G C Brain; Pamela S Ganschow; Kelly K Hunt; Deborah K Mayer; Kathryn J Ruddy; Reshma Jagsi; Nancy U Lin; Beverly Canin; Barbara K LeStage; Anna C Revette; Mara A Schonberg; Nancy L Keating Journal: JAMA Oncol Date: 2021-04-01 Impact factor: 33.006
Authors: Maximilian Präger; Marion Kiechle; Björn Stollenwerk; Christoph Hinzen; Jürgen Glatz; Matthias Vogl; Reiner Leidl Journal: PLoS One Date: 2018-06-01 Impact factor: 3.240